Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Electronic Resource  (2)
  • Diabetes mellitus  (1)
  • Myeloproliferative Störungen  (1)
  • 1
    ISSN: 1432-0584
    Keywords: Androgene ; Myeloproliferative Störungen ; Anämie ; Thrombopenie ; Androgens ; Myeloproliferative disorder ; Anemia ; Thrombocytopenia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary In order to study the effect of oxymetholone therapy in advanced myelofibrosis, 11 patients (4 females, 7 males) were given, 3–5 mg per kg body weight, long-term oxymetholone treatment in a prospective multicenter study. Five cases had previously had a diagnosis of polycythemia vera. All patients had anemia initially, 4 leukocytopenia and 10 thrombocytopenia in addition. Hepato-splenomegaly was present in all cases but in varying degree. Five patients required regular blood transfusions before treatment. In 9 of the 15 courses given, there was normalization of the peripheral blood or substantial improvement (better than 3 g hemoglobin/dl or 50×109 platelets/1) after androgens. Significant effects were noted both on hemoglobin values and platelet counts. The need for blood transfusions ceased completely in all 5 cases. When oxymetholone treatment was reduced or interrupted 4 patients relapsed; 2 of them responded to a renewed course. The red cell counts returned to previous polycythemic values in one patient and another died from acute leukemia. The results of this study suggest that androgens might be of value in advanced cases of myelofibrosis with transfusion-requiring anemia or severe thrombocytopenia.
    Notes: Zusammenfassung Die therapeutische Wirksamkeit von Oxymetholon bei fortgeschrittener Osteomyeloflbrose wurde im Rahmen einer prospektiven Studie geprüft. 11 Patienten (4 Frauen, 7 Männer) erhielten 3–5 mg/kg Körpergewicht Oxymetholon. 5 dieser Patienten hatten vorher eine polyzythämische Phase. Alle Patienten hatten bei Beginn des Therapieversuchs eine Anämie, 4 eine Leukopenie und 10 zusätzlich eine Thrombopenie. Eine Hepatosplenomegalie war immer vorhanden. 5 Patienten benötigten vor Behandlung regelmäßig Bluttransfusionen. In 9 von 15 Therapiephasen wurde eine Normalisierung und deutliche Besserung beobachtet. Die Veränderungen des Hämoglobinspiegels und der Plättchenzahl waren signifikant. 4 Patienten verschlechterten sich nach Dosisreduktion oder bei Absetzen von Oxymetholon; 2 davon sprachen erneut an. Bei einem Patienten kehrten die Werte zu den früher bestehenden polyzythämischen Werten zurück. 1 Patient starb durch eine akute Leukämie. Die Ergebnisse der Studie weisen daraufhin, daß Androgene in weit fortgeschrittenen Fällen von Myelofibrose mit transfusionsbedürftiger Anämie oder schwerer Zytopenie von Wert sein könnte.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0428
    Keywords: Diabetes mellitus ; polyneuropathy ; sorbitol accumulation ; aldose reductase inhibitor ; clinical trial
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The effects of the aldose reductase inhibitor, sorbinil, on symptomatic symmetrical diabetic polyneuropathy were studied during a 6-month period in a double-blind parallel group placebo-controlled trial. Twenty-seven patients received sorbinil and 28 placebo. The patients were assessed by clinical examination, neurophysiological measurements, sensory threshold determinations and tests of autonomic nerve function. No major clinical benefit was seen in the sorbiniltreated patients and no differences in sensory thresholds were observed. In three out of nine neurophysiological tests (motor nerve conduction velocity of the posterior tibial nerve, F-wave latency and sensory distal latency of the ulnar nerve) and one out of five tests of autonomic nerve function (heart rate variation during deep breathing) significant differences between the patient groups evolved in favour of sorbinil treatment. An overall evaluation of the temporal development of these and remaining neurophysiological and autonomic variables suggested a small but significant benefit from sorbinil treatment. There was no evidence of continuing improvement throughout the treatment period and beneficial effects observed were no greater than those seen in previous trials of considerably shorter treatment periods. It is concluded that sorbinil treatment results in some improvement in peripheral nerve function in symptomatic diabetic polyneuropathy, but that the long-term effect may be of limited value.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...